MiniMed Appoints Board of Directors as Independent Company
Diabetes technology company MiniMed has announced its new nine-member Board of Directors following its separation from Medtronic. The board composition reflects the company's priorities as an independent public entity focused on growth and innovation.
NORTHRIDGE, Calif. – October 15, 2026 – Diabetes technology company MiniMed (Nasdaq: MMED) has announced the composition of its Board of Directors, following its separation from Medtronic. This new board reflects MiniMed's priorities as an independent public company, emphasizing focused growth, continued innovation, disciplined execution, and broader access to diabetes technology.
The board's collective experience spans healthcare delivery and access, medical technology, manufacturing operations, corporate governance, and consumer engagement. Kevin E. Lofton continues as Chair of the Board. Amy Bricker and Tim L. Main are joining the board immediately as part of the planned transition from Medtronic-designated directors.
"As an independent public company, MiniMed has a clear mission: reduce the burden of diabetes management and make integrated technology easier to access and use," said Que Dallara, Chief Executive Officer of MiniMed. "That requires a Board that understands healthcare access and patient needs, and can also help us execute across technology, commercial operations, manufacturing, finance and governance."
The new nine-member board includes individuals with extensive experience in healthcare leadership, medical technology, manufacturing, and public company governance, such as Kevin E. Lofton, former CEO of CommonSpirit Health; Amy Bricker, Executive Vice President, Enterprise Pharmacy at Walgreens; and David Endicott, CEO of Alcon.